Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:30:57 05/12/2025 GMT			5-day change	1st Jan Change
310.90 ^CHF	+0.26%		+1.14%	+21.68%

12-05	ROCHE HOLDINGS AG : Gets a Buy rating from UBS	ZD
12-04	Women can self-test at home for cervical cancer virus, new guidelines say	RE

Health Care Up After Strong Earnings -- Health Care Roundup

Published on 11/18/2025 at 10:15 pm GMT

Dow Jones

Roche Holding AG

+0.26%

Medtronic plc

-0.62%

Health-care companies rose amid strong earnings and defensive bias.

Shares of medical-device maker Medtronic advanced after it raised its fiscal-year outlook after logging higher profit and sales in its latest quarter, boosted by robust demand across end markets and healthy procedure volumes.

Roche Holding shares rallied after the Swiss drug maker said its breast-cancer drug showed promise in clinical trials

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

11-18-25 1714ET

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	ROCHE HOLDING AG	310.90CHF	+0.26%	+1.14%	330B
	MEDTRONIC PLC	101.36USD	-0.62%	-3.77%	130B

Latest news about Roche Holding AG

12-05	ROCHE HOLDINGS AG : Gets a Buy rating from UBS	ZD
12-04	Women can self-test at home for cervical cancer virus, new guidelines say	RE
12-04	Orano Med Enters Next Phase of Collaboration with Roche	CI
12-03	China Introduces Drug Price Registration System	MT
12-02	Swiss Stocks Remain in Green; Roche Shares Gain	MT
12-02	US FDA Green-lights Roche's First Point-of-care Test for Whooping Cough	MT
12-02	Berenberg Ups Roche Price Target Amid Upside Pipeline Surprise, Expected 'Solid' Momentum	MT
12-02	Roche's test for diagnosing whooping cough receives FDA clearance	RE
12-02	Roche Receives FDA Clearance with CLIA waiver and CE Mark for its First Point-Of-Care Test for Diagnosing Bordetella Infections, Including Whooping Cough	CI
12-01	ROCHE HOLDINGS AG : Berenberg reiterates its Neutral rating	ZD
11-27	STOXX 600 ends steady after multiple-session rally; Puma, Allfunds jump on takeover buzz	RE
11-26	UK Regulator Approves Roche's Targeted Treatment for Advanced Breast Cancer	MT
11-25	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
11-25	Novartis plans to cut up to 550 jobs at Swiss facility	RE
11-20	Swiss trade surplus at CHF 4.32 bln in October	RE
11-19	KaliVir Immunotherapeutics announces clinical trial collaboration and supply agreement with Roche	RE
11-19	Kalivir Immunotherapeutics, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Vet3-Tgi in Combination with Atezolizumab (Tecentriq®?) in Advanced Solid Tumors	CI
11-19	ROCHE HOLDINGS AG : Deutsche Bank reaffirms its Neutral rating	ZD
11-19	ROCHE HOLDINGS AG : UBS maintains a Buy rating	ZD
11-19	Roche Obtains Conditional Marketing Permit in EU for Lymphoma Treatment Lunsumio Subcutaneous	MT
11-19	European Commission approves Roche's Lunsumio subcutaneous for relapsed or refractory follicular lymphoma	RE
11-19	European Commission Approves Roche's Lunsumio Subcutaneous for Relapsed or Refractory Foothicular Lymphoma	CI
11-18	Health Care Up After Strong Earnings -- Health Care Roundup	DJ
11-18	Swiss Market Index Closes Lower; Roche Shares Up	MT
11-18	ROCHE HOLDINGS AG : Jefferies maintains a Sell rating	ZD

Chart Roche Holding AG

Duration

Period

ROG: Dynamic Chart

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Employees

103,249

Sector

Pharmaceuticals

Calendar

07/12/2025 - American Society of Hematology Meeting - Poster Number - #3743

More about the company